← Back to all trials
Recruiting
NCT02325674
MEASuRE: Metreleptin Effectiveness And Safety Registry
Conditions: Generalised Lipodystrophy, Partial Lipodystrophy
Sex: All
Healthy volunteers: No
Enrollment: 100
Sponsor: Chiesi Farmaceutici S.p.A.
Location: University Alabama at Birmingham Birmingham Alabama
Summary
The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.
Eligibility Criteria
Inclusion Criteria:
* Patients treated with metreleptin through commercial supply at the time or before enrolment into registry
* Patients who provide a written consent
* Patient coming off metreleptin clinical studies and continuing or restarting treatment with metreleptin through commercial supply
Exclusion Criteria:
• Patients currently treated with an investigational agent as part of a clinical trial
Source: ClinicalTrials.gov (NCT02325674). StuddyBuddy aggregates publicly available trial information.
